Real-world data on the prevalence of BRCA1/2 and HRR gene mutations in patients with primary and metastatic castration resistant prostate cancer.
Moritz HommerdingOliver HommerdingMarit BernhardtTobias KreftChristine SandersVerena TischlerPatrick BasittaNatalie PelusiAnna-Lena WulfCarsten-Henning OhlmannJörg EllingerManuel RitterGlen KristiansenPublished in: World journal of urology (2024)
This study offers valuable real-world insights into the landscape of BRCA1/2 and HRR gene mutations and the practical clinical management of HRR gene testing in prostate cancer, contributing to a better understanding of patient eligibility for PARPi treatment.
Keyphrases
- prostate cancer
- squamous cell carcinoma
- small cell lung cancer
- radical prostatectomy
- risk factors
- case report
- electronic health record
- genome wide
- copy number
- big data
- gene expression
- single cell
- breast cancer risk
- dna methylation
- combination therapy
- data analysis
- genome wide identification
- deep learning
- artificial intelligence